UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000020370 |
|---|---|
| Receipt number | R000023525 |
| Scientific Title | Phase 2 trial of the efficacy and safety of Afatinib for EGFR-TKI untreated EGFR gene mutation-Positive Elderly advanced or recurrent non-small cell lung Cancer. (APEC) |
| Date of disclosure of the study information | 2015/12/27 |
| Last modified on | 2018/12/30 11:22:41 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Phase 2 trial of the efficacy and safety of Afatinib for EGFR-TKI untreated EGFR gene mutation-Positive Elderly advanced or recurrent non-small cell lung Cancer. (APEC)
Acronym
Phase II trial of afatinib treatment for elderly non-small cell lung cancer patients with EGFR gene mutations
Scientific Title
Phase 2 trial of the efficacy and safety of Afatinib for EGFR-TKI untreated EGFR gene mutation-Positive Elderly advanced or recurrent non-small cell lung Cancer. (APEC)
Scientific Title:Acronym
Phase II trial of afatinib treatment for elderly non-small cell lung cancer patients with EGFR gene mutations
Region
| Japan |
Condition
Condition
Non-small cell lung cancer
Classification by specialty
| Pneumology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To investigate the efficacy and safety of afatinib monotherapy for elderly non-small cell lung cancer patients with EGFR gene mutations
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Confirmatory
Trial characteristics_2
Pragmatic
Developmental phase
Phase II
Assessment
Primary outcomes
Progression-free survval
Key secondary outcomes
Safety, Respose rate, and overall survival
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Daily 30mg of afatinib is orally administered until tumor progression or the onset of untolerable adverse events.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 75 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1) Patients who are cytologically or histologically diagnosed with non-small cell clung cancer
2) Patients with non-small cell lung cancer harboring EGFR gene mutations (exon19 deletion, exon21 L858R, exon18 G719X, exon20 S768I, or exon21 L861Q) using tissue specimens or lavage fluid including pleural effusion
3) EGFR tyrosine kinase inhibitor-naive patients with the following stages
a) stage IIIA with pulmonary metastases
b) stage IIIB without indication of curative radiation therapy
c) stage IV
d) postoperative recurrence
4) Patients with measurable lesions acccording to RECIST criteria
5) Patients who are expected to survive more than 90 days from the time of enrollment
6) More than 75-year old patients at the time of enrollment
7) Patients who meet the following criteria
a) Neutrophil; more than 1,500/mm3
b) Platelet; more than 100,000/mm3
c) Hemoglobin; more than 9.0g/dL
d) Transaminases (AST and ALT); within 2.5XULN (institutional reference values)
e) Serum total bilirubin (T-Bil); within 1.5XULN
f) Serum creatinine (S-Cr); within 1.5XULN
g) PaO2 in arterial blood gas; more than 60Torr or SpO2; more than 90%
8) Performance status (ECOG) of 0-2
9) Patients who provide written informed consent for entry of this trial
Key exclusion criteria
1) Patients with active double cancers (simultaneous double cancers and metachronous double cancers with less than 5 years disease-free interval)
Exclusion: carcinoma in situ of cervix, gastric and colorectal cancers which can be radically resected by endoscope, and locally-resectable skin cancer except malignant melanoma
2) Patients with apparent interstitial pneumonia or pulmonary fibrosis on chest computed tomography
3) Patients with symptomatic brain metastases
Exclusion: patients who have had stable symptoms more than 2 weeks after radiation therapy or more than 4 weeks after surgery
4) Patients with active infection
5) Patients requring continuous oxgen therapy
6) Patients who are in pregnancy or intend to get pregnant
7) Patients with a history of serious drug allergy
8) Patients with other serious complications
9) Patients with a history of allergy for a component of afatinib
10) Patients who are considered to have difficulty in enrollment of this trial based on clinically important psychiatric reasons
11) Patients who are considered to be inappropriate in enrollment of this trial by attending physicians
Target sample size
40
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Nobuyuki Koyama |
Organization
Tokyo Medical University Hachioji Medical Center
Division name
Department of Clinical Oncology
Zip code
Address
1163 Tatemachi, Hachioji-shi, Tokyo, 193-0998, Japan
TEL
042-665-5611
nkoyama@tokyo-med.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Yasutaka Watanabe |
Organization
Tokyo Medical University Hachioji Medical Center
Division name
Department of Clinical Oncology
Zip code
Address
1163 Tatemachi, Hachioji-shi, Tokyo, 193-0998, Japan
TEL
042-665-5611
Homepage URL
yasuyasu@tokyo-med.ac.jp
Sponsor or person
Institute
Saitama Lung Cancer Research Group
Institute
Department
Personal name
Funding Source
Organization
None
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
東京医科大学八王子医療センター（東京都）、自治医科大学附属さいたま医療センター（埼玉県）、春日部市立病院（埼玉県）、春日部中央総合病院（埼玉県）、川口市立医療センター（埼玉県）、埼玉県立循環器・呼吸器病センター（埼玉県）、さいたま赤十字病院（埼玉県）、草加市立病院（埼玉県）、東京医科大学八王子医療センター（東京都）
Other administrative information
Date of disclosure of the study information
| 2015 | Year | 12 | Month | 27 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Terminated
Date of protocol fixation
| 2015 | Year | 05 | Month | 18 | Day |
Date of IRB
Anticipated trial start date
| 2015 | Year | 08 | Month | 01 | Day |
Last follow-up date
| 2019 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2015 | Year | 12 | Month | 27 | Day |
Last modified on
| 2018 | Year | 12 | Month | 30 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023525
| Research Plan | |
|---|---|
| Registered date | File name |
| 2018/06/29 | 研究実施計画書0528.docx |
| Research case data specifications | |
|---|---|
| Registered date | File name |
| 2018/06/29 | Vol.1.1症例登録用紙(Afatinib).docx |
| Research case data | |
|---|---|
| Registered date | File name |
| 2018/06/29 | Vol.1.1症例登録用紙(Afatinib).docx |
